Zheng Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4092511/publications.pdf

Version: 2024-02-01

		20817	6471
173	28,446	60	157
papers	citations	h-index	g-index

191	191	191	47653
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Structure-Based Discovery and Structural Basis of a Novel Broad-Spectrum Natural Product against the Main Protease of Coronavirus. Journal of Virology, 2022, 96, JVI0125321.	3.4	20
2	Partial nephrectomy through retroperitoneal approach with a new surgical robot system, KDâ€SRâ€01. International Journal of Medical Robotics and Computer Assisted Surgery, 2022, 18, e2352.	2.3	8
3	Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice. Virology Journal, 2022, 19, 2.	3.4	15
4	Clinical Predictors of Functional Cure in Children 1â€“6 Years-old with Chronic Hepatitis B. Journal of Clinical and Translational Hepatology, 2022, 10, 405-411.	1.4	2
5	CD127 imprints functional heterogeneity to diversify monocyte responses in inflammatory diseases. Journal of Experimental Medicine, 2022, 219, .	8.5	21
6	Potent antibody immunity to SARSâ€CoVâ€2 variants elicited by a third dose of inactivated vaccine. Clinical and Translational Medicine, 2022, 12, e732.	4.0	14
7	Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209. Cell Research, 2022, 32, 491-494.	12.0	17
8	The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year. Emerging Microbes and Infections, 2022, 11, 753-756.	6.5	7
9	A prophylactic effect of aluminium-based adjuvants against respiratory viruses via priming local innate immunity. Emerging Microbes and Infections, 2022, 11, 914-925.	6.5	8
10	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. IScience, 2022, 25, 104043.	4.1	19
11	Effectiveness of adjuvant radiotherapy for high recurrence risk patients with upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	1
12	12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single-Center Prospective Cohort Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 864933.	3.9	17
13	Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization. Journal of Clinical Virology, 2022, 150-151, 105162.	3.1	7
14	A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARSâ€CoVâ€2 variants including BA.1 and BA.2 in vaccinated mice. Journal of Medical Virology, 2022, , .	5.0	5
15	Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants. IScience, 2022, 25, 104431.	4.1	3
16	Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron. Virology Journal, 2022, 19, .	3.4	5
17	Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection. Journal of Infection, 2022, 85, 418-427.	3.3	20
18	Clinical status of patients 1Âyear after hospital discharge following recovery from COVID-19: a prospective cohort study. Annals of Intensive Care, 2022, 12, .	4.6	13

#	Article	IF	Citations
19	The determination of release from isolation of COVID-19 patients requires ultra-high sensitivity nucleic acid test technology. Journal of Infection, 2021, 82, 159-198.	3.3	5
20	Prediction of the Receptorome for the Human-Infecting Virome. Virologica Sinica, 2021, 36, 133-140.	3.0	11
21	Identification and characterization of circRNAs encoded by MERS-CoV, SARS-CoV-1 and SARS-CoV-2. Briefings in Bioinformatics, 2021, 22, 1297-1308.	6.5	37
22	Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial. Emerging Microbes and Infections, 2021, 10, 1589-1597.	6.5	41
23	Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis. Virulence, 2021, 12, 1209-1226.	4.4	16
24	Prokaryotic virus host predictor: a Gaussian model for host prediction of prokaryotic viruses in metagenomics. BMC Biology, 2021, 19, 5.	3.8	50
25	Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers. Frontiers in Medicine, 2021, 8, 595773.	2.6	42
26	Distinct kinetics of immunoglobulin isotypes reveal early diagnosis and disease severity of COVIDâ€19: A 6â€month followâ€up. Clinical and Translational Medicine, 2021, 11, e342.	4.0	8
27	Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. Cell Research, 2021, 31, 517-525.	12.0	54
28	Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes. Virology Journal, 2021, 18, 87.	3.4	27
29	COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell, 2021, 184, 1895-1913.e19.	28.9	512
30	Association between vasectomy and risk of prostate cancer: a meta-analysis. Prostate Cancer and Prostatic Diseases, 2021, 24, 962-975.	3.9	4
31	Metabolic Defects of Peripheral T Cells in COVID-19 Patients. Journal of Immunology, 2021, 206, 2900-2908.	0.8	17
32	Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes. PLoS Biology, 2021, 19, e3001209.	5.6	31
33	Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 697074.	4.8	18
34	Reshaping cell line development and <scp>CMC</scp> strategy for fast responses to pandemic outbreak. Biotechnology Progress, 2021, 37, e3186.	2.6	20
35	ScRNA-seq revealed the kinetic of nasopharyngeal immune responses in asymptomatic COVID-19 carriers. Cell Discovery, 2021, 7, 56.	6.7	7
36	Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial. Chinese Medical Journal, 2021, 134, 1967-1976.	2.3	24

#	Article	IF	Citations
37	Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Research, 2021, 31, 1011-1023.	12.0	48
38	Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nature Communications, 2021, 12, 4210.	12.8	82
39	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity, 2021, 54, 1611-1621.e5.	14.3	190
40	Suppressive Monocytes Impair MAIT Cells Response via IL-10 in Patients with Severe COVID-19. Journal of Immunology, 2021, 207, 1848-1856.	0.8	14
41	Dysregulated hematopoiesis in bone marrow marks severe COVID-19. Cell Discovery, 2021, 7, 60.	6.7	46
42	SCIGA: Software for large-scale, single-cell immunoglobulin repertoire analysis. GigaScience, 2021, 10, .	6.4	0
43	Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nature Communications, 2021, 12, 5652.	12.8	49
44	Multiomics: unraveling the panoramic landscapes of SARS-CoV-2 infection. Cellular and Molecular Immunology, 2021, 18, 2313-2324.	10.5	31
45	Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nature Communications, 2021, 12, 250.	12.8	108
46	Relationship Between the ABO Blood Group and the Coronavirus Disease 2019 (COVID-19) Susceptibility. Clinical Infectious Diseases, 2021, 73, 328-331.	5.8	444
47	SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation. Cell Research, 2021, 31, 1230-1243.	12.0	62
48	The concentrated antibody from convalescent plasma balanced the dysfunctional immune responses in patients with critical COVIDâ€19. Clinical and Translational Medicine, 2021, 11, e571.	4.0	1
49	Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies. Cell Discovery, 2021, 7, 112.	6.7	14
50	The Transient IFN Response and the Delay of Adaptive Immunity Feature the Severity of COVID-19. Frontiers in Immunology, 2021, 12, 816745.	4.8	9
51	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. Frontiers in Immunology, 2021, 12, 766821.	4.8	15
52	Clinical Characteristics and Surgical Management of Adult Adrenal Teratoma: A 15-year Experience and Systematic Review of the Literature. Urology, 2020, 135, 71-75.	1.0	6
53	Dissecting the human immune system with single cell RNA sequencing technology. Journal of Leukocyte Biology, 2020, 107, 613-623.	3.3	13
54	The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET. Structure, 2020, 28, 1218-1224.e4.	3.3	140

#	Article	IF	Citations
55	Clinical characteristics of recovered COVID-19 patients with re-detectable positive RNA test. Annals of Translational Medicine, 2020, 8, 1084-1084.	1.7	128
56	The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. Cell Discovery, 2020, 6, 73.	6.7	188
57	Reply to Nagappa and Marimuthu. Clinical Infectious Diseases, 2020, 71, 3016-3017.	5.8	0
58	Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 2271-2277.	2.9	92
59	CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduction and Targeted Therapy, 2020, 5, 283.	17.1	806
60	Persistent viral activity, cytokine storm, and lung fibrosis in a case of severe COVIDâ€19. Clinical and Translational Medicine, 2020, 10, e224.	4.0	7
61	Longitudinal Changes on Clinical Features in 28 Children With COVID-19 in Shenzhen, China. Frontiers in Medicine, 2020, 7, 579406.	2.6	3
62	Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 2020, 584, 115-119.	27.8	1,524
63	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell, 2020, 182, 1401-1418.e18.	28.9	663
64	Metabolic defects in splenic B cell compartments from patients with liver cirrhosis. Cell Death and Disease, 2020, 11, 915.	6.3	3
65	Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. Journal of Allergy and Clinical Immunology, 2020, 146, 119-127.e4.	2.9	553
66	Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients. Cell, 2020, 181, 1475-1488.e12.	28.9	405
67	Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nature Medicine, 2020, 26, 842-844.	30.7	2,083
68	Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering, 2020, 6, 1192-1198.	6.7	989
69	Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. National Science Review, 2020, 7, 1003-1011.	9.5	202
70	Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochemical and Biophysical Research Communications, 2020, 526, 135-140.	2.1	758
71	Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA - Journal of the American Medical Association, 2020, 323, 1582.	7.4	1,921
72	Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical Infectious Diseases, 2020, 71, 2027-2034.	5.8	2,214

#	Article	IF	Citations
73	Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients. Science China Life Sciences, 2020, 63, 606-609.	4.9	112
74	Sustained IFN-I stimulation impairs MAIT cell responses to bacteria by inducing IL-10 during chronic HIV-1 infection. Science Advances, 2020, 6, eaaz0374.	10.3	27
75	Phage protein receptors have multiple interaction partners and high expressions. Bioinformatics, 2020, 36, 2975-2979.	4.1	12
76	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences, 2020, 63, 364-374.	4.9	1,606
77	FluPhenotypeâ€"a one-stop platform for early warnings of the influenza A virus. Bioinformatics, 2020, 36, 3251-3253.	4.1	7
78	Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host and Microbe, 2020, 27, 325-328.	11.0	1,860
79	Single-cell RNA sequencing reveals the heterogeneity of liver-resident immune cells in human. Cell Discovery, 2020, 6, 22.	6.7	137
80	Early Virus Clearance and Delayed Antibody Response in a Case of Coronavirus Disease 2019 (COVID-19) With a History of Coinfection With Human Immunodeficiency Virus Type 1 and Hepatitis C Virus. Clinical Infectious Diseases, 2020, 71, 2233-2235.	5.8	93
81	Cell membrane proteins with high N-glycosylation, high expression and multiple interaction partners are preferred by mammalian viruses as receptors. Bioinformatics, 2019, 35, 723-728.	4.1	31
82	Rapid identification of humanâ€infecting viruses. Transboundary and Emerging Diseases, 2019, 66, 2517-2522.	3.0	31
83	Hyperactive Follicular Helper T Cells Contribute to Dysregulated Humoral Immunity in Patients With Liver Cirrhosis. Frontiers in Immunology, 2019, 10, 1915.	4.8	15
84	A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B. Clinical and Translational Gastroenterology, 2019, 10, e00033.	2.5	5
85	High levels of circulating GM-CSF+CD4+ T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study. Cellular and Molecular Immunology, 2019, 16, 602-610.	10.5	34
86	Predicting the receptor-binding domain usage of the coronavirus based on kmer frequency on spike protein. Infection, Genetics and Evolution, 2018, 61, 183-184.	2.3	55
87	Humoral immunity, the underestimated player in hepatitis B. Cellular and Molecular Immunology, 2018, 15, 645-648.	10.5	16
88	C/EBPÎ² promotes the viability of human bladder cancer cell by contributing to the transcription of bladder cancer specific lncRNA UCA1. Biochemical and Biophysical Research Communications, 2018, 506, 674-679.	2.1	8
89	Infection and depletion of CD4+ group-1 innate lymphoid cells by HIV-1 via type-I interferon pathway. PLoS Pathogens, 2018, 14, e1006819.	4.7	19
90	Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. Clinical Gastroenterology and Hepatology, 2017, 15, 132-136.	4.4	166

#	Article	IF	Citations
91	Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma. Cancer Biology and Therapy, 2017, 18, 51-62.	3.4	20
92	Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Hepatology, 2017, 66, 1067-1082.	7.3	44
93	Activated hepatic stellate cells impair NK cell anti-fibrosis capacity through a TGF-Î²-dependent emperipolesis in HBV cirrhotic patients. Scientific Reports, 2017, 7, 44544.	3.3	53
94	PTTG1, A novel androgen responsive gene is required for androgen-induced prostate cancer cell growth and invasion. Experimental Cell Research, 2017, 350, 1-8.	2.6	12
95	Current advances in the elimination of hepatitis B in China by 2030. Frontiers of Medicine, 2017, 11, 490-501.	3.4	58
96	HIV-1 infection depletes human CD34+CD38- hematopoietic progenitor cells via pDC-dependent mechanisms. PLoS Pathogens, 2017, 13, e1006505.	4.7	35
97	A novel chemotherapeutic sensitivity-testing system based on collagen gel droplet embedded 3Dâ€“culture methods for hepatocellular carcinoma. BMC Cancer, 2017, 17, 729.	2.6	31
98	Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis. Oncotarget, 2017, 8, 96725-96731.	1.8	4
99	The Influence of Tumor Size on Oncologic Outcomes for Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy. BioMed Research International, 2016, 2016, 1-7.	1.9	16
100	Low expression of CXCR1/2 on neutrophils predicts poor survival in patients with hepatitis B virus-related acute-on-chronic liver failure. Scientific Reports, 2016, 6, 38714.	3.3	31
101	Reply. Hepatology, 2016, 63, 348-348.	7.3	0
102	Regulation of T cell function by microRNA-720. Scientific Reports, 2015, 5, 12159.	3.3	20
103	Predictive role of preoperative hydronephrosis on poor pathological outcomes and prognosis in upper tract urothelial carcinoma patients: Experience from a nationwide high-volume center in China. Oncology Letters, 2015, 10, 3113-3122.	1.8	10
104	Reply. Hepatology, 2015, 62, 1640-1641.	7.3	0
105	Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Humanâ€“Mouse Chimeric and Glycoengineered Antibody. Molecular Cancer Therapeutics, 2015, 14, 162-173.	4.1	23
106	microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Molecular Cancer, 2015, 14, 5.	19.2	108
107	Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cellular and Molecular Immunology, 2015, 12, 309-316.	10.5	78
108	CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology, 2015, 61, 627-638.	7.3	104

#	Article	IF	Citations
109	Plasmacytoid dendritic cells promote HIV-1â€“induced group 3 innate lymphoid cell depletion. Journal of Clinical Investigation, 2015, 125, 3692-3703.	8.2	66
110	Impaired Function of CD4+ T Follicular Helper (Tfh) Cells Associated with Hepatocellular Carcinoma Progression. PLoS ONE, 2015, 10, e0117458.	2.5	77
111	Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: Incidence and risk factors. World Journal of Gastroenterology, 2015, 21, 3554.	3.3	31
112	Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China. International Journal of Clinical and Experimental Medicine, 2015, 8, 1205-12.	1.3	14
113	Myeloid-Derived Suppressor Cells Are Associated with Viral Persistence and Downregulation of TCR Î¶ Chain Expression on CD8+ T Cells in Chronic Hepatitis C Patients. Molecules and Cells, 2014, 37, 66-73.	2.6	47
114	Hepatitis B Virus Infection and Immunopathogenesis in a Humanized Mouse Model: Induction of Human-Specific Liver Fibrosis and M2-Like Macrophages. PLoS Pathogens, 2014, 10, e1004032.	4.7	191
115	The global burden of liver disease: The major impact of China. Hepatology, 2014, 60, 2099-2108.	7.3	986
116	Interleukinâ€21 mediates hepatitis <scp>B</scp> virusâ€associated liver cirrhosis by activating hepatic stellate cells. Hepatology Research, 2014, 44, E198-205.	3.4	14
117	Renal Cell Carcinoma With Infrahepatic Vena Caval Tumor Thrombus Treated With a Novel Combined Retroperitoneal and Transperitoneal Pure Laparoscopic Procedure. Urology, 2014, 83, e9-e10.	1.0	8
118	Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology, 2014, 59, 1331-1342.	7.3	150
119	The role of neutrophils in the development of liver diseases. Cellular and Molecular Immunology, 2014, 11, 224-231.	10.5	188
120	Long non-coding RNA urothelial carcinoma associated 1 induces cell replication by inhibiting BRG1 in 5637 cells. Oncology Reports, 2014, 32, 1281-1290.	2.6	54
121	Complement 5a stimulates hepatic stellate cells in vitro, and is increased in the plasma of patients with chronic hepatitis B. Immunology, 2013, 138, 228-234.	4.4	22
122	A pilot study of umbilical cordâ€derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 85-92.	2.8	153
123	Stem cell therapies for liver failure and cirrhosis. Journal of Hepatology, 2013, 59, 183-185.	3.7	86
124	Impairment of CD4⁺cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology, 2013, 58, 139-149.	7.3	163
125	Decreased VÎ2 Î³Î´ T Cells Associated With Liver Damage by Regulation of Th17 Response in Patients With Chronic Hepatitis B. Journal of Infectious Diseases, 2013, 208, 1294-1304.	4.0	31
126	How can acute-on-chronic liver failure be accurately identified?. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 390-391.	17.8	23

#	Article	IF	Citations
127	Upregulation of <scp>OX</scp>40 ligand on monocytes contributes to early virological control in patients with chronic hepatitis <scp>C</scp>. European Journal of Immunology, 2013, 43, 1953-1962.	2.9	11
128	Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. Aids, 2013, 27, 1283-1293.	2.2	66
129	Hypoxia upregulates CD147 through a combined effect of HIF-1Î± and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors. Carcinogenesis, 2012, 33, 1598-1607.	2.8	96
130	Human Mesenchymal Stem Cell Transfusion Is Safe and Improves Liver Function in Acute-on-Chronic Liver Failure Patients. Stem Cells Translational Medicine, 2012, 1, 725-731.	3.3	287
131	Natural Killer Cells Are Characterized by the Concomitantly Increased Interferon-Î³ and Cytotoxicity in Acute Resolved Hepatitis B Patients. PLoS ONE, 2012, 7, e49135.	2.5	51
132	Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 112-120.	2.8	294
133	Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 223-230.	2.8	56
134	Comparison of laparoscopic and open cystectomy for bladder cancer: a single center of 110 cases report. Translational Andrology and Urology, 2012, 1, 4-8.	1.4	13
135	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. Science, 2011, 333, 1593-1602.	12.6	788
136	Hyper-Activated Pro-Inflammatory CD16+ Monocytes Correlate with the Severity of Liver Injury and Fibrosis in Patients with Chronic Hepatitis B. PLoS ONE, 2011, 6, e17484.	2.5	101
137	Promoter hypomethylation upâ€regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2011, 15, 1415-1428.	3.6	57
138	New strategy for large-scale preparation of the extracellular domain of tumor-associated antigen HAb18G/CD147 (HAb18GED). Journal of Bioscience and Bioengineering, 2011, 111, 1-6.	2.2	9
139	Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology, 2011, 53, 73-85.	7.3	141
140	B and T Lymphocyte Attenuator Down-regulation by HIV-1 Depends on Type I Interferon and Contributes to T-Cell Hyperactivation. Journal of Infectious Diseases, 2011, 203, 1668-1678.	4.0	30
141	Increased Turnover of FoxP3high Regulatory T Cells Is Associated With Hyperactivation and Disease Progression of Chronic HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 455-462.	2.1	31
142	Interleukin-17-producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology, 2010, 51, 81-91.	7.3	332
143	Decreased Ratio of Treg Cells to Th17 Cells Correlates with HBV DNA Suppression in Chronic Hepatitis B Patients Undergoing Entecavir Treatment. PLoS ONE, 2010, 5, e13869.	2.5	77
144	Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Review of Gastroenterology and Hepatology, 2009, 3, 499-512.	3.0	59

#	Article	IF	Citations
145	Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. Clinical Immunology, 2009, 132, 43-54.	3.2	27
146	Progressive CD127 downâ€regulation correlates with increased apoptosis of CD8 T cells during chronic HIVâ€1 infection. European Journal of Immunology, 2009, 39, 1425-1434.	2.9	18
147	The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8⁺ T cells in HIVâ€1â€infected typical progressors, but not in longâ€term nonâ€progressors. Immunology, 2009, 128, e366-75.	4.4	83
148	HAb18G (CD147), a cancerâ€associated biomarker and its role in cancer detection. Histopathology, 2009, 54, 677-687.	2.9	161
149	Viral suppression correlates with dendritic cell restoration in chronic hepatitis B patients with autologous cytokineâ€induced killer cell transfusion. Liver International, 2009, 29, 466-474.	3.9	6
150	Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. Journal of Hepatology, 2009, 50, 1163-1173.	3.7	44
151	Compartmentalization and its implication for peripheral immunologicallyâ€competent cells to the liver in patients with HBVâ€related acuteâ€onâ€chronic liver failure. Hepatology Research, 2009, 39, 1198-1207.	3.4	38
152	Imbalanced Intrahepatic Cytokine Expression of Interferon-Î³, Tumor Necrosis Factor-Î±, and Interleukin-10 in Patients With Acute-on-Chronic Liver Failure Associated With Hepatitis B Virus Infection. Journal of Clinical Gastroenterology, 2009, 43, 182-190.	2.2	86
153	B7â€H1 upâ€regulation impairs myeloid DC and correlates with disease progression in chronic HIVâ€1 infection. European Journal of Immunology, 2008, 38, 3226-3236.	2.9	55
154	Activated plasmacytoid dendritic cells act synergistically with hepatitis B core antigen-pulsed monocyte-derived dendritic cells in the induction of hepatitis B virus-specific CD8 T-cell response. Clinical Immunology, 2008, 129, 295-303.	3.2	14
155	Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clinical Immunology, 2008, 129, 428-437.	3.2	259
156	Dynamic Programmed Death 1 Expression by Virus-Specific CD8 T Cells Correlates With the Outcome of Acute Hepatitis B. Gastroenterology, 2008, 134, 1938-1949.e3.	1.3	152
157	Crystal Structure of HAb18G/CD147. Journal of Biological Chemistry, 2008, 283, 18056-18065.	3.4	114
158	Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. Journal of Hepatology, 2008, 49, 396-406.	3.7	95
159	Cutting Edge: Programmed Death-1 Up-Regulation Is Involved in the Attrition of Cytomegalovirus-Specific CD8+ T Cells in Acute Self-Limited Hepatitis B Virus Infection. Journal of Immunology, 2008, 181, 3741-3744.	0.8	27
160	B7-H1 Up-Regulation on Myeloid Dendritic Cells Significantly Suppresses T Cell Immune Function in Patients with Chronic Hepatitis B. Journal of Immunology, 2007, 178, 6634-6641.	0.8	118
161	PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood, 2007, 109, 4671-4678.	1.4	259
162	Response to interferon-Î± treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B. Journal of Hepatology, 2007, 47, 751-759.	3.7	17

#	Article	IF	Citations
163	Increased Regulatory T Cells Correlate With CD8 T-Cell Impairment and Poor Survival in Hepatocellular Carcinoma Patients. Gastroenterology, 2007, 132, 2328-2339.	1.3	743
164	A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. Hepatology, 2007, 45, 269-276.	7.3	168
165	Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B. Clinical Immunology, 2007, 122, 173-180.	3.2	57
166	The high prevalence of the I27 mutant HBcAg18â€“27 epitope in Chinese HBV-infected patients and its cross-reactivity with the V27 prototype epitope. Clinical Immunology, 2007, 125, 337-345.	3.2	25
167	Biodistribution and localization of iodine-131 labeled metuximab in patients with hepatocellular carcinoma. Cancer Biology and Therapy, 2006, 5, 318-322.	3.4	34
168	Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical Phase I/II trials. International Journal of Radiation Oncology Biology Physics, 2006, 65, 435-444.	0.8	140
169	Differential Restoration of Myeloid and Plasmacytoid Dendritic Cells in HIV-1-Infected Children after Treatment with Highly Active Antiretroviral Therapy. Journal of Immunology, 2006, 176, 5644-5651.	0.8	51
170	Rapid Identification of UCA1 as a Very Sensitive and Specific Unique Marker for Human Bladder Carcinoma. Clinical Cancer Research, 2006, 12, 4851-4858.	7.0	417
171	Longitudinal alteration of circulating dendritic cell subsets and its correlation with steroid treatment in patients with severe acute respiratory syndrome. Clinical Immunology, 2005, 116, 225-235.	3.2	23
172	SARS-Associated Coronavirus Quasispecies in Individual Patients. New England Journal of Medicine, 2004, 350, 1366-1367.	27.0	82
173	SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. Frontiers in Immunology, 0, 13, .	4.8	10